Cabozantinib with Aspirin: Additive Bleeding Risk, Do Not Stop Cardiac Aspirin Alone, Urgent Warning Signs

　　1.Core Risk of Combining

　　Cabozantinib is a multi-kinase inhibitor with a labeled warning for severe and sometimes fatal hemorrhage;grade 3 bleeding events occur more often than with placebo,and recent hemoptysis or bleeding history makes use not recommended.It can be associated with mucosal injury,thrombocytopenia,hypertension,and tumor-related fistula or erosion backgrounds that predispose to bleeding.

　　Aspirin acetylates platelet cyclo-oxygenase-1,reduces thromboxane A2,and produces irreversible antiplatelet effect lasting the platelet lifetime of about 7–10 days.Enteric coating reduces gastric irritation but does not remove systemic bleeding risk.

　　The combination matters because:

　　cabozantinib raises the bleeding substrate in mucosa/vessels;

　　aspirin removes platelet plug formation;

　　minor bleeding may become persistent,and occult GI,urinary,or intracranial bleeding is harder to notice.

　　The same caution applies to clopidogrel,warfarin,DOACs,and NSAIDs such as ibuprofen.

　　2.Who Needs Extra Caution

　　Do not add or continue blindly if the patient has:

　　active or recent GI bleed,melena,hematemesis;

　　peptic ulcer,varices,severe gastritis,recent endoscopic hemostasis;

　　hemoptysis,lung lesion adjacent to large vessels,tracheoesophageal fistula risk;

　　prior intracranial hemorrhage,uncontrolled hypertension;

　　thrombocytopenia,coagulopathy,significant hepatic/renal impairment;

　　concurrent anticoagulants,dual antiplatelet therapy,NSAIDs,steroids;

　　older age,low body weight,severe diarrhea/dehydration on TKI.

　　Cabozantinib labeling does not recommend use in patients with recent bleeding or hemoptysis.If aspirin is already prescribed,the decision is not simply“stop cancer drug”or“stop aspirin”but balancing oncology urgency against bleeding history,platelet count,and GI status.

　　3.Aspirin for Cardiac or Stroke Prevention

　　If aspirin is used for coronary artery disease,secondary stroke prevention,post-stent therapy,or mechanical valve,it should not be stopped by the patient when cabozantinib starts.Self-stopping antiplatelet therapy can trigger stent thrombosis,myocardial infarction,or ischemic stroke,often a greater threat than local bleeding.

　　Practical rules:

　　Tell the oncology team the aspirin dose,indication,duration,and whether clopidogrel is also used;

　　Oncology plus cardiology/neurology decide whether to continue low-dose aspirin,switch antiplatelet strategy,or briefly modify;

　　Do not self-increase aspirin,do not swap to clopidogrel informally,do not add aspirin“for prevention”;

　　If cabozantinib must be held for bleeding,the prescriber manages it;

　　Taking the two drugs at different times does not undo aspirin’s platelet inhibition.

　　Common scenarios:

　　Stable CAD on low-dose aspirin,low bleed history:often continue with monitoring;

　　Recent stent dual antiplatelet:usually keep aspirin;cardiology decides clopidogrel;

　　Active ulcer/black stool history:gastroenterology review first—PPI,H.pylori,ulcer healing;

　　Active hemoptysis in lung cancer:cabozantinib may be inappropriate;aspirin also re-evaluated.

　　4.Monitoring and Administration

　　Cabozantinib:empty stomach at least 1 hour before or 2 hours after food,avoid grapefruit;

　　Aspirin enteric tablet:swallow whole,do not chew;follow original administration instruction;

　　Monitor CBC,platelets,stool color/occult blood for long-term aspirin,blood pressure,LFT/RFT;check INR if on warfarin;

　　Record epistaxis,gum bleeding,bruises,urine color,headache,dizziness;

　　Avoid alcohol and self-added ibuprofen/diclofenac/celecoxib;

　　Before surgery,dental extraction,endoscopy,or biopsy,disclose both drugs early.

　　Perioperative hold is not patient-driven:aspirin timing depends on stent age,bleeding risk of the procedure,and thrombosis risk;dual antiplatelet or recent stent cases need surgeon+cardiology+oncology.

　　5.Urgent Warning Signs

　　Seek care immediately for:

　　hematemesis or coffee-ground vomit;

　　black tarry stool,maroon stool;

　　hematuria,unexpected vaginal bleeding,wound oozing;

　　nosebleed not controlled after 10 minutes;

　　sudden severe headache,vomiting,blurred vision,one-sided weakness;

　　dizziness,palpitations,pallor,syncope from possible blood loss;

　　coughing up blood;

　　abdominal pain with cold sweat or tachycardia.

　　Mild gum bleeding or small bruise can be observed and reported,but with cabozantinib the threshold should be lower,especially if anticoagulants,DAPT,or NSAIDs are also used.